NCT02889367View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics and the Effect on Cardiac Repolarization of Odalasvir Administered as a Single Dose Tablet Under Fed Conditions in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 12, 2016

Primary Completion Date

March 4, 2017

Study Completion Date

March 4, 2017

Conditions

Healthy

Interventions

DRUG

Odalasvir 100 mg

Participants will receive odalasvir 2\*50 mg tablet, orally once on Day 1.

DRUG

Placebo

Participants will receive odalasvir matching placebo, tablet, orally once on Day 1.

DRUG

Odalasvir 500 mg

Participants will receive odalasvir 10\*50 mg tablet, orally once on Day 1.

DRUG

Odalasvir (Up to maximum 1000 mg)

Participants will receive odalasvir to be decided up to maximum of 20\*50 mg tablet, orally once on Day 1.

Trial Locations (1)

Unknown

Tempe

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT02889367 - A Study to Evaluate the Pharmacokinetics and the Effect on Cardiac Repolarization of Odalasvir Administered as a Single Dose Tablet Under Fed Conditions in Healthy Participants | Biotech Hunter | Biotech Hunter